Multicenter,Randomized,Double-blind,Placebo,Parallel-controlled,Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2018
At a glance
- Drugs LY 03005 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Luye Pharma Group
- 21 Dec 2018 New source identified and integrated (ClinicalTrials.gov NCT03785652).
- 02 Feb 2018 New trial record
- 23 Jan 2018 According to a Luye Pharma Group media release, primary endpoint (Reduction in 17- item Hamilton Rating Scale) has been met.